Mineralys (MLYS) CEO Jon Congleton Sells 10,700 Shares

What Happened Jon Congleton, CEO of Mineralys Therapeutics (MLYS), sold 10,700 shares on July 13, 2026 in an open‑market sale. The weighted‑average price was $27.24 per share, generating approximately $291,441 in proceeds. The sale is reported with transaction code "S" (sale).

Key Details

• Transaction date: July 13, 2026 (reported on Form 4 filed July 15, 2026) — filing appears timely.
• Price: weighted‑average $27.24; actual sale prices ranged from $26.80 to $27.58.
• Total proceeds: ~$291,441.
• Plan: Transactions were made pursuant to a Rule 10b5‑1 trading plan adopted January 28, 2025 (footnote F1).
• Footnote: The weighted‑average price is reported; the reporting person will provide per‑price breakdowns on request (footnote F2).
• Shares owned after transaction: not disclosed in the supplied filing details.

Context Sales executed under a pre‑arranged 10b5‑1 plan are typically scheduled in advance and are often considered routine liquidity events rather than direct signals of company prospects. This was a straight sale of existing shares (no option exercise, award, or gift involved).